STRONGPOINT
23.6.2021 08:02:07 CEST | Business Wire | Press release
StrongPoint ASA , a leading European grocery retail solution provider, today announces its grocery e-commerce picking solution, designed specifically for grocery retailers looking for fast, hyper-efficient and scalable e-commerce logistics solutions. The Strongpoint solution suite delivers industry-leading efficiency rates with many in-store associates averaging ~240 items picked per labor hour across all product categories, compared with common industry standards of 60-65 items per hour.
Hosted on StrongPoint’s cloud-based SaaS e-commerce platform, the Order Picking solution helps retailers capitalize on the growing opportunity of online grocery, driving greater efficiency and higher productivity rates. It also reduces labor costs associated with the fulfillment of online orders, while enhancing customer convenience and protecting margins.
StrongPoint launched its first Order Picking solution more than 20 years ago. Since then, it has undergone countless iterations, changes and updates based on customer feedback over two decades of usage by thousands of pickers in multiple countries. A key benefit of StrongPoint’s cloud-based solution is that grocery retailers receive continuous updates as the team finds new opportunities to drive efficiency gains.
Since the start of the pandemic, Bain estimates adoption of online grocery in the US and Western Europe has accelerated between two and five years and this sustained demand is set to continue2 . Despite the explosion in demand, both for grocery e-commerce and q-commerce, retailers have struggled to make online grocery profitable, with the high cost of labor hours allocated to picking and the fulfillment of e-commerce orders ebbing away at already squeezed margins.
StrongPoint’s solution was born out of 35+ years’ experience in responding to the rapidly evolving needs of leading grocery retailers across multiple European countries. Its grocery e-commerce Order Picking solution delivers unprecedented efficiencies compared to orders that are picked manually, by empowering staff with its proprietary software technology.
Many of StrongPoint’s grocery retail customers who are utilizing the full functionalities of the solution are able to reach average in-store picking rates of ~240 items per labor hour across all product categories, compared with a common industry standard of 60-65 items per labor hour when using traditional solutions. In addition, StrongPoint’s Order Picking solution averages 99.99% accuracy, making it on par with leading fully automated grocery fulfillment solutions.
Its hyper-efficient orchestration technology customizes the picking route for the store associate, creating the most effective order sequencing for picking, based on the unique layout and footprint of each store. Other standard features include picking by temperature zones, multiple solutions for age-restricted items and substitution options.
The solution, which can be deployed in large and small format settings with the option of using Zebra hardware devices for maximum efficiency, includes multi-zone and multi-order picking capabilities to drive even greater efficiencies. It can integrate with in-built store hardware, such as electronic shelf labels (ESLs), allowing store associates to “pick to light” to increase speed and order accuracy. In addition, there is the option of integrating a smart trolley that has been purpose-built for maximum ergonomic efficiency. Data inputs at each stage of the picking process – from preparing the trolley to the picking, weighing, and bagging of products – create a continuous feedback loop, so ergonomic improvements can be made to drive further efficiencies, speed and accuracy.
“We are proud to unveil our latest technology solution, specifically designed to help grocery retailers leverage their stores and cater to the exponential growth of e-commerce,” said Jacob Tveraabak, CEO at StrongPoint. “Having worked with grocery retailers for over three decades, we understand the importance of driving speed, efficiency and scalability across their operations in the stores – and that was intrinsic in how we developed the latest iteration of our grocery e-commerce Order Picking solution.”
-ENDS-
Notes to editors
StrongPoint is a retail technology company that provides solutions to make shops smarter, shopping experiences better and online grocery shopping more efficient.
With over 450 employees in Norway, Sweden, the Baltics and Spain and, together with a wide partner network, StrongPoint supports businesses in more than 20 countries.
StrongPoint is headquartered in Norway and is listed on the Oslo Stock Exchange.
For more information, visit https://www.strongpoint.com/
1
https://www.mwpvl.com/MWPVL_International_-_Micro_Fulfillment_Centers_-_Passing_Fad_or_Permanent_Market_Shift.pdf
2
https://www.bain.com/insights/the-next-five-years-in-online-grocery-snap-chart/
View source version on businesswire.com: https://www.businesswire.com/news/home/20210622005819/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex Announces US FDA Approval for Label Extensions of ALYFTREK® and TRIKAFTA®, Expanding Availability of These Medicines to ~95% of All People With CF in the United States1.4.2026 13:30:00 CEST | Press release
-With this expansion, any variant that results in production of CFTR protein is now included in the indication for ALYFTREK and TRIKAFTA, reinforcing the impact these medicines have, regardless of the location of the variant in the CFTR protein--Approximately 800 more people with CF in the US are now eligible for a CFTR modulator for the first time- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) has approved expanded use of ALYFTREK® (vanzacaftor/tezacaftor/ivacaftor) for the treatment of people with cystic fibrosis (CF) ages 6 and older with a variant in the cystic fibrosis transmembrane conductance regulator (CFTR) gene that is either responsive based on clinical and/or in vitro data or results in production of CFTR protein. Additionally, the U.S. FDA has also expanded the indication statement for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in patients ages 2 and older. This label expansion was supported b
Agenus Announces First Patient Enrolled in Global Phase 3 BATTMAN Trial of BOT+BAL Immunotherapy Combination in MSS or pMMR Metastatic Colorectal Cancer1.4.2026 13:30:00 CEST | Press release
A Landmark Registrational Study Aiming to Redefine Outcomes in MSS mCRC Which Represents Approximately 95% of Metastatic Colorectal Cancer CasesColorectal Cancer Has Become the Leading Cause of Cancer-related Death in Adults Under Age 50 Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that the first patient has been enrolled in the landmark global phase 3 BATTMAN (CO.33) trial (NCT07152821). This study is evaluating Agenus’ immunotherapy combination of botensilimab (BOT) plus balstilimab (BAL) versus best supportive care in patients with refractory, unresectable microsatellite stable (MSS)/mismatch repair proficient (pMMR) metastatic colorectal cancer (mCRC), a population long considered resistant to immunotherapy. This study is being conducted as a cooperative group trial led by the Canadian Cancer Trials Group (CCTG) from Canada and run across Canada, France, Australia and New Zealand. More than 100 sites will participate across the academic cooper
Klarna Agrees to $1.7 Billion Transaction Supporting up to $40B+ of Lending1.4.2026 13:19:00 CEST | Press release
Klarna, the global digital bank and flexible payments provider, has entered into a new capital efficiency transaction in the form of a Significant Risk Transfer (SRT), covering $1.7 billion-worth of Euro denominated loans and freeing up capital to support continued growth. Klarna has entered into a three-year agreement with a consortium led by Värde Partners. This is Klarna's sixth SRT transaction and improves how effectively Klarna deploys its capital on a global basis. "Our banking license is one of our biggest competitive advantages," said Niclas Neglén, Klarna's Chief Financial Officer. "This is our largest and most efficient SRT transaction to date. These transactions allow us to maximize every unit of capital to support our continued momentum." The transaction follows Klarna’s recently announced $2 billion facility supporting $17B of US Financing expansion. About Klarna Klarna is a global digital bank and flexible payments provider. With over 118 million global active Klarna user
Americhem Launches nDryve™: PFAS-Free In-Melt Technology Platform for Functional Fibers1.4.2026 13:00:00 CEST | Press release
Americhem, Inc., a global polymer solutions provider, today announced the launch of nDryve™, a PFAS-free, in-melt surface-modifying technology platform designed to deliver durable multi-fluid repellency against alcohol and other low-surface-energy fluids in fiber systems. As global regulations accelerate the phase-out of per- and polyfluoroalkyl substances (PFAS), manufacturers are under increasing pressure to maintain barrier performance without fluorinated chemistries. nDryve™ was developed to address this shift, offering a PFAS-free, in-melt alternative to conventional surface applied treatments. Engineered for Performance Without PFAS Often referred to as “forever chemicals,” PFAS have come under heightened regulatory scrutiny due to their persistence and potential environmental and health impacts. nDryve™ integrates directly into the polymer during melt processing, embedding surface-modifying functionality within the fiber matrix rather than relying on removable finishes. By engin
Biocytogen and Sihuan Pharmaceutical Announce Strategic Partnership in Weight Loss and Beyond1.4.2026 13:00:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced a strategic partnership with Sihuan Pharmaceutical Holdings Group Ltd. (Sihuan Pharmaceutical; HKEX: 00460). Under the agreement, both parties will combine Biocytogen’s leading fully human antibody discovery platform with Sihuan Pharmaceutical’s extensive capabilities in drug development, manufacturing, and commercialization. The collaboration will focus on advancing innovative therapies across multiple disease areas, including weight loss, leveraging complementary strengths to drive synergies and establish a long-term strategic partnership. Sihuan Pharmaceutical highly values the strength of Biocytogen’s technology platforms. In this collaboration, Biocytogen will leverage its integrated platforms, including proprietary target-humanized mouse models and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
